Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision oncology therapies to address unmet medical needs in hematologic malignancies. The company leverages insights into the genetic and epigenetic profiles of cancers to advance a pipeline of novel, small-molecule kinase inhibitors. Its lead clinical-stage candidates include tuspetinib (HM43239), an oral myeloid kinase inhibitor, and luxeptinib (CG-806), a dual lymphoid and myeloid kinase inhibitor. These therapies are designed to provide single-agent efficacy and enhance existing anti-cancer regimens without overlapping toxicities.